PARP1 and glioblastoma: In combination with TMZ, the PARP inhibitor niraparib enhances immune recognition by upregulating NKG2DL, leading to increased ULBP1/Mult-1 mRNA expression and improved gamma-delta T cell-mediated cytotoxicity in GBM patient-derived xenografts.369